Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell entities : Nurix therapeutics, inc. save search
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
NRIX 6 d | $14.125 4.01% 3.86% 690K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment solid tumors potential therapy drug clearance t-cell
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
NRIX 6 d | $14.125 4.01% 3.86% 690K
|
Health Technology
|
| O: 9.5%
H: 15.97%
C: 8.74%
phase 1 trial phase 1b t-cell
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
Published: 2021-10-26 (Crawled : 22:00) - biospace.com/
NRIX 6 d | $14.125 4.01% 3.86% 690K
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
phase 1 trial t-cell
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.